Company Data

Unicycive Therapeutics Inc.

Fundamental Analysis:

Unicycive Therapeutics Inc.

Unicycive Therapeutics Inc.
Fundamental Analysis:
Current Price
$0.4 -1.82%
Market Cap
Price Target
Refer to Report
52wk Range
$0.339 - $1.818
Advanced Market Data


Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. For more information, please visit and follow us on LinkedIn and YouTube.

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy